Assessment Status |
Full HTA submission received from Applicant |
HTA ID |
23004 |
Drug |
Ropeginterferon alfa-2b |
Brand |
Besremi® |
Indication |
Ropeginterferon alfa-2b is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly. |
Rapid review commissioned |
20/01/2023 |
Rapid review completed |
15/03/2023 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ropeginterferon alfa-2b compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
29/03/2023 |
Pre-submission consultation with Applicant |
03/05/2023 |
Full submission received from Applicant |
20/07/2023 |